Those who interrupted GLP-1 treatment and subsequently resumed before the end of the three-year trial period experienced less benefit compared to those who stayed on the medication, with longer gaps in treatment corresponding to smaller reductions in cardiovascular risk
Individuals are able to reduce their caloric intake with more resolve and less difficulty, right
Larger, well-designed studies are needed to confirm whether GLP-1 therapies are safe and effective for alcohol and other substance use disorders and to understand who might benefit most and how best to use them
Metabolic Syndrome Resolution Post-hoc analysis of SURPASS trials demonstrated substantial reductions in metabolic syndrome prevalence: Significant improvements in multiple cardiovascular risk factors simultaneously Reductions in blood pressure, improved lipid profiles, and decreased waist circumference Resolution of metabolic syndrome criteria in a substantial proportion of participants Potential long-term cardiovascular benefits from comprehensive metabolic improvements Cardiovascular and Metabolic Comorbidities Heart Failure with Preserved Ejection Fraction (HFpEF) The SUMMIT phase 3 trial evaluated GLP2 in adults with HFpEF and obesity: Statistically significant reduction in heart failure outcomes (composite endpoint) Improvements in heart failure symptoms and physical limitations measured by Kansas City Cardiomyopathy Questionnaire Enhanced exercise capacity as measured by 6-Minute Walk Test Distance Reduction in high-sensitivity C-reactive protein (inflammation marker) These findings established GLP2 as the first incretin therapy to demonstrate benefits on heart failure outcomes in this population
Some good news: Telogen effluvium is typically not considered permanent
Across published clinical trial work, researchers have studied it for weight management, weight reduction, body composition, fat loss, appetite suppression, and broader metabolic regulation, with reported doses up to 12mg by subcutaneous injection
